Potential Interactions of Hypertension Drug in Medan City Pharmacy
Background: Hypertension is a disease that can cause complications without the patient realizing it. Therapeutic management needed to control the patient's blood pressure is complex enough to potentially lead to drug interactions. The purpose of this study was to analyze the interaction of hypertension drugs that occurred in a pharmacy in the city of Medan.
Method: The study was conducted retrospectively involving 101 patient data in February-May 2022. Patient data was processed descriptively and potential drug interactions were analyzed using the Medscape Drug Interactions Checker, Stockley's Drug Interaction, and the drugs.com database
Result: Based on the study results, it was found that from 101 patients, 57 patients had no drug interactions (56.4%), but 45 cases of drug interactions were found in 44 patients (43.6%). Drug interactions found in 27 cases occurred pharmacokinetically (60%) and 18 cases occurred pharmacodynamically (40%). The most frequent drug interactions are Amlodipine and Simvastatin.
Conclusion: Based on this study, it can be concluded that most patients who have drug interactions occur through pharmacokinetic mechanisms.
2. Kementerian Kesehatan Republik Indonesia . Riset kesehatan dasar Republik Indonesia. Jakarta: Kementerian Kesehatan Republik Indonesia. 2013.
3. Kementerian Kesehatan Republik Indonesia Riset kesehatan dasar Republik Indonesia Jakarta: Kementerian Kesehatan Republik Indonesia. 2013.
4. Leung A.A, Daskalopoulou S.S, & Dasgupta K. Hypertension Canada’s guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33:557–576.
5. Kusumawardani L.A, Andrajati R, & Nusaibah A. Drug-related problems in hypertensive patients: A cross-sectional study from Indonesia. J Res Pharm Pract. 2020; 9:140-5.
6. Samaila, Aliyu, Biambo, Aminu, Usman, & Nuruddeen. Drug related problems and implications for pharmaceutical care interventions in hypertensive outpatients in a Nigerian hospital. Journal of Science and Practice of Pharmacy. 2019; 17. 69-78.
7. Van Mil J.W.F, Horvat N, & Zuidlaren T.W. Classification for Drug Related Problems V9.0. Pharmaceutical Care Network Europe Foundation (PCNE). 2019.
8. Parulian L, Listyanti E, Hati A.K, & Sunnah I. Analisis Hubungan Polifarmasi dan Interaksi Obat Pada Pasien Rawat Jalan Yang Mendapat Obat Hipertensi Di Rsp. Dr. Ario Wirawan Periode Januari-Maret 2019. Indonesian Journal of Pharmacy and Natural Product. 2019; Volume 2. No 2.
9. Stockley I.H. Stockley’s Drug Interaction. 8th Edition. Pharmaceutical Press. 2008. Great Britain.
10. Drug.com Database. 2022. (online), https://www.drugs.com/interaction/, accessed on 2 August 2022.
11. Medscape. Drug Interaction Checker. 2011 (online), (http://www.reference.medscape.com/drug interactionchecker), accessed on 1 August 2022.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).